Biocryst Pharmaceuticals, Inc. splits its revenue into 5 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Product at $172.3 million, 96% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2026
|
Q3 FY2026
Sep 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
962
|
180
|
218
|
156
|
407
|
159
|
163
|
146
|
132
|
| Product |
—
|
172
+9.2%
share 95.6%
|
158
-3.0%
share 72.2%
|
—
|
159
+23.1%
share 39.2%
|
158
share 99.0%
|
162
share 99.4%
|
144
share 98.8%
|
129
share 98.3%
|
| License And Other Revenues |
—
|
8
share 4.4%
|
61
+6480.4%
share 27.8%
|
—
|
247
share 60.8%
|
—
|
1
share 0.6%
|
2
share 1.2%
|
—
|
| License Revenue And Other Income From Contract With Customer |
—
|
5
+1616.7%
share 3.0%
|
60
+821.5%
share 27.5%
|
—
|
11
+48.2%
share 2.7%
|
0
share 0.2%
|
7
share 4.0%
|
11
share 7.8%
|
7
share 5.6%
|
| License |
—
|
—
|
—
|
3
share 1.9%
|
—
|
—
|
—
|
—
|
—
|
| Collaborative And Other Research And Development |
—
|
—
|
—
|
2
+14.3%
share 1.3%
|
3
+54.1%
share 0.8%
|
2
share 1.0%
|
—
|
2
share 1.2%
|
2
share 1.7%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- BCRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Durham, NC
- SEC filer status
- Large accelerated filer
- SEC CIK
- 882796
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.